Clinical Trial Update: Effectiveness and Safety Study for RWJ-333369 as Adjunctive Therapy in Korean and Japanese Patients With Partial Onset Seizures [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating RWJ-333369 as adjunctive therapy for partial onset seizures in Korean and Japanese patients was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Partial-onset Seizures

Drugs mentioned

• RWJ 333369 (RWJ-333369)

Snippet

Sponsor: SK Life Science, Inc. | Conditions: Seizures | Phase 3 | Status: TERMINATED